Cell death modulation via antagonists of fasl and fas...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01) C07K 14/705 (2006.01)

Patent

CA 2563691

The invention provides a peptide that blocks the activation of Fas, TNFR1, or both. The peptide can be used to treat conditions associated with dysregulation of the cell death pathway and can be administered as a pharmaceutical composition.

L'invention concerne un polypeptide atténuant l'activation du récepteur Fas, du récepteur TNFR1 ou des deux. Ce polypeptide peut être utilisé pour traiter des états associés à une dysrégulation de la voie de mort cellulaire ou inflammatoire et peut être formulé sous forme de compositions pharmaceutiques à usage médical ou vétérinaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cell death modulation via antagonists of fasl and fas... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell death modulation via antagonists of fasl and fas..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell death modulation via antagonists of fasl and fas... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1392137

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.